Search

Your search keyword '"Datwani, Sneha"' showing total 14 results
Start Over Author "Datwani, Sneha"
14 results on '"Datwani, Sneha"'

1. Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy

Author

Lapointe, Hope R., Mwimanzi, Francis, Cheung, Peter K., Sang, Yurou, Yaseen, Fatima, Speckmaier, Sarah, Barad, Evan, Moran-Garcia, Nadia, Datwani, Sneha, Duncan, Maggie C., Kalikawe, Rebecca, Ennis, Siobhan, Young, Landon, Ganase, Bruce, Omondi, F. Harrison, Umviligihozo, Gisele, Dong, Winnie, Toy, Junine, Sereda, Paul, Burns, Laura, Costiniuk, Cecilia T., Cooper, Curtis, Anis, Aslam H., Leung, Victor, Holmes, Daniel, DeMarco, Mari L., Simons, Janet, Hedgcock, Malcolm, Prystajecky, Natalie, Lowe, Christopher F., Romney, Marc G., Barrios, Rolando, Guillemi, Silvia, Brumme, Chanson J., Montaner, Julio S.G., Hull, Mark, Harris, Marianne, Niikura, Masahiro, Brockman, Mark A., and Brumme, Zabrina L.

Published
2023
Full Text
View/download PDF

2. T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy

Author

Datwani, Sneha, primary, Kalikawe, Rebecca, additional, Waterworth, Rachel, additional, Mwimanzi, Francis M., additional, Liang, Richard, additional, Sang, Yurou, additional, Lapointe, Hope R., additional, Cheung, Peter K., additional, Omondi, Fredrick Harrison, additional, Duncan, Maggie C., additional, Barad, Evan, additional, Speckmaier, Sarah, additional, Moran-Garcia, Nadia, additional, DeMarco, Mari L., additional, Hedgcock, Malcolm, additional, Costiniuk, Cecilia T., additional, Hull, Mark, additional, Harris, Marianne, additional, Romney, Marc G., additional, Montaner, Julio S. G., additional, Brumme, Zabrina L., additional, and Brockman, Mark A., additional

Published
2024
Full Text
View/download PDF

3. Dynamics of T-cell Responses Following COVID-19 mRNA Vaccination and Breakthrough Infection in Older Adults

Author

Datwani, Sneha, primary, Kalikawe, Rebecca, additional, Mwimanzi, Francis, additional, Speckmaier, Sarah, additional, Liang, Richard, additional, Sang, Yurou, additional, Waterworth, Rachel, additional, Yaseen, Fatima, additional, Lapointe, Hope, additional, Barad, Evan, additional, DeMarco, Mari, additional, Holmes, Daniel, additional, Simons, Janet, additional, Montaner, Julio, additional, Romney, Marc, additional, Brumme, Zabrina, additional, and Brockman, Mark, additional

Published
2023
Full Text
View/download PDF

4. Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine

Author

Mwimanzi, Francis, primary, Lapointe, Hope R, additional, Cheung, Peter K, additional, Sang, Yurou, additional, Yaseen, Fatima, additional, Kalikawe, Rebecca, additional, Datwani, Sneha, additional, Burns, Laura, additional, Young, Landon, additional, Leung, Victor, additional, Ennis, Siobhan, additional, Brumme, Chanson J, additional, Montaner, Julio S G, additional, Dong, Winnie, additional, Prystajecky, Natalie, additional, Lowe, Christopher F, additional, DeMarco, Mari L, additional, Holmes, Daniel T, additional, Simons, Janet, additional, Niikura, Masahiro, additional, Romney, Marc G, additional, Brumme, Zabrina L, additional, and Brockman, Mark A, additional

Published
2023
Full Text
View/download PDF

5. Antibody response durability following three-dose COVID-19 vaccination in people with HIV receiving suppressive ART

Author

Lapointe, Hope R., primary, Mwimanzi, Francis, additional, Cheung, Peter K., additional, Sang, Yurou, additional, Yaseen, Fatima, additional, Speckmaier, Sarah, additional, Barad, Evan, additional, Moran-Garcia, Nadia, additional, Datwani, Sneha, additional, Duncan, Maggie C., additional, Kalikawe, Rebecca, additional, Ennis, Siobhan, additional, Young, Landon, additional, Ganase, Bruce, additional, Omondi, F. Harrison, additional, Umviligihozo, Gisele, additional, Dong, Winnie, additional, Toy, Junine, additional, Sereda, Paul, additional, Burns, Laura, additional, Costiniuk, Cecilia T., additional, Cooper, Curtis, additional, Anis, Aslam H., additional, Leung, Victor, additional, Holmes, Daniel, additional, Demarco, Mari L., additional, Simons, Janet, additional, Hedgcock, Malcolm, additional, Prystajecky, Natalie, additional, Lowe, Christopher F., additional, Romney, Marc G., additional, Barrios, Rolando, additional, Guillemi, Silvia, additional, Brumme, Chanson J., additional, Montaner, Julio S.G., additional, Hull, Mark, additional, Harris, Marianne, additional, Niikura, Masahiro, additional, Brockman, Mark A., additional, and Brumme, Zabrina L., additional

Published
2022
Full Text
View/download PDF

6. Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination

Author

Lapointe, Hope R., primary, Mwimanzi, Francis, additional, Cheung, Peter K., additional, Sang, Yurou, additional, Yaseen, Fatima, additional, Kalikawe, Rebecca, additional, Datwani, Sneha, additional, Waterworth, Rachel, additional, Umviligihozo, Gisele, additional, Ennis, Siobhan, additional, Young, Landon, additional, Dong, Winnie, additional, Kirkby, Don, additional, Burns, Laura, additional, Leung, Victor, additional, Holmes, Daniel T., additional, DeMarco, Mari L., additional, Simons, Janet, additional, Matic, Nancy, additional, Montaner, Julio S.G., additional, Brumme, Chanson J., additional, Prystajecky, Natalie, additional, Niikura, Masahiro, additional, Lowe, Christopher F., additional, Romney, Marc G., additional, Brockman, Mark A., additional, and Brumme, Zabrina L., additional

Published
2022
Full Text
View/download PDF

7. Impact of age and SARS-CoV-2 breakthrough infection on humoral immune responses after three doses of COVID-19 mRNA vaccine

Author

Mwimanzi, Francis, primary, Lapointe, Hope R., additional, Cheung, Peter K., additional, Sang, Yurou, additional, Yaseen, Fatima, additional, Kalikawe, Rebecca, additional, Datwani, Sneha, additional, Burns, Laura, additional, Young, Landon, additional, Leung, Victor, additional, Ennis, Siobhan, additional, Brumme, Chanson J., additional, Montaner, Julio S.G., additional, Dong, Winnie, additional, Prystajecky, Natalie, additional, Lowe, Christopher F., additional, DeMarco, Mari L., additional, Holmes, Daniel T., additional, Simons, Janet, additional, Niikura, Masahiro, additional, Romney, Marc G., additional, Brumme, Zabrina L., additional, and Brockman, Mark A., additional

Published
2022
Full Text
View/download PDF

8. People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses.

Author

Lapointe, Hope R, Mwimanzi, Francis, Cheung, Peter K, Sang, Yurou, Yaseen, Fatima, Umviligihozo, Gisele, Kalikawe, Rebecca, Speckmaier, Sarah, Moran-Garcia, Nadia, Datwani, Sneha, Duncan, Maggie C, Agafitei, Olga, Ennis, Siobhan, Young, Landon, Ali, Hesham, Ganase, Bruce, Omondi, F Harrison, Dong, Winnie, Toy, Junine, and Sereda, Paul

Subjects
SARS-CoV-2, COVID-19, HIV, ANTIRETROVIRAL agents, CORONAVIRUS diseases, VACCINATION
Abstract

Background Longer-term humoral responses to 2-dose coronavirus disease 2019 (COVID-19) vaccines remain incompletely characterized in people living with human immunodeficiency virus (HIV) (PLWH), as do initial responses to a third dose. Methods We measured antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain, angiotensin-converting enzyme 2 (ACE2) displacement, and viral neutralization against wild-type and Omicron strains up to 6 months after 2-dose vaccination, and 1 month after the third dose, in 99 PLWH receiving suppressive antiretroviral therapy and 152 controls. Results Although humoral responses naturally decline after 2-dose vaccination, we found no evidence of lower antibody concentrations or faster rates of antibody decline in PLWH compared with controls after accounting for sociodemographic, health, and vaccine-related factors. We also found no evidence of poorer viral neutralization in PLWH after 2 doses, nor evidence that a low nadir CD4+ T-cell count compromised responses. Post–third-dose humoral responses substantially exceeded post–second-dose levels, though Omicron-specific responses were consistently weaker than responses against wild-type virus. Nevertheless, post–third-dose responses in PLWH were comparable to or higher than controls. An mRNA-1273 third dose was the strongest consistent correlate of higher post–third-dose responses. Conclusion PLWH receiving suppressive antiretroviral therapy mount strong antibody responses after 2- and 3-dose COVID-19 vaccination. Results underscore the immune benefits of third doses in light of Omicron. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

10. People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses

Author

Lapointe, Hope R, primary, Mwimanzi, Francis, additional, Cheung, Peter K, additional, Sang, Yurou, additional, Yaseen, Fatima, additional, Umviligihozo, Gisele, additional, Kalikawe, Rebecca, additional, Speckmaier, Sarah, additional, Moran-Garcia, Nadia, additional, Datwani, Sneha, additional, Duncan, Maggie C, additional, Agafitei, Olga, additional, Ennis, Siobhan, additional, Young, Landon, additional, Ali, Hesham, additional, Ganase, Bruce, additional, Omondi, F Harrison, additional, Dong, Winnie, additional, Toy, Junine, additional, Sereda, Paul, additional, Burns, Laura, additional, Costiniuk, Cecilia T, additional, Cooper, Curtis, additional, Anis, Aslam H, additional, Leung, Victor, additional, Holmes, Daniel T, additional, DeMarco, Mari L, additional, Simons, Janet, additional, Hedgcock, Malcolm, additional, Prystajecky, Natalie, additional, Lowe, Christopher F, additional, Pantophlet, Ralph, additional, Romney, Marc G, additional, Barrios, Rolando, additional, Guillemi, Silvia, additional, Brumme, Chanson J, additional, Montaner, Julio S G, additional, Hull, Mark, additional, Harris, Marianne, additional, Niikura, Masahiro, additional, Brockman, Mark A, additional, and Brumme, Zabrina L, additional

Published
2022
Full Text
View/download PDF

11. Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose

Author

Mwimanzi, Francis, primary, Lapointe, Hope R, additional, Cheung, Peter K, additional, Sang, Yurou, additional, Yaseen, Fatima, additional, Umviligihozo, Gisele, additional, Kalikawe, Rebecca, additional, Datwani, Sneha, additional, Omondi, F Harrison, additional, Burns, Laura, additional, Young, Landon, additional, Leung, Victor, additional, Agafitei, Olga, additional, Ennis, Siobhan, additional, Dong, Winnie, additional, Basra, Simran, additional, Lim, Li Yi, additional, Ng, Kurtis, additional, Pantophlet, Ralph, additional, Brumme, Chanson J, additional, Montaner, Julio S G, additional, Prystajecky, Natalie, additional, Lowe, Christopher F, additional, DeMarco, Mari L, additional, Holmes, Daniel T, additional, Simons, Janet, additional, Niikura, Masahiro, additional, Romney, Marc G, additional, Brumme, Zabrina L, additional, and Brockman, Mark A, additional

Published
2022
Full Text
View/download PDF

12. People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses

Author

Lapointe, Hope R., primary, Mwimanzi, Francis, additional, Cheung, Peter K., additional, Sang, Yurou, additional, Yaseen, Fatima, additional, Umviligihozo, Gisele, additional, Kalikawe, Rebecca, additional, Speckmaier, Sarah, additional, Moran-Garcia, Nadia, additional, Datwani, Sneha, additional, Duncan, Maggie C., additional, Agafitei, Olga, additional, Ennis, Siobhan, additional, Young, Landon, additional, Ali, Hesham, additional, Ganase, Bruce, additional, Omondi, F. Harrison, additional, Dong, Winnie, additional, Toy, Junine, additional, Sereda, Paul, additional, Burns, Laura, additional, Costiniuk, Cecilia T., additional, Cooper, Curtis, additional, Anis, Aslam H., additional, Leung, Victor, additional, Holmes, Daniel, additional, DeMarco, Mari L., additional, Simons, Janet, additional, Hedgcock, Malcolm, additional, Prystajecky, Natalie, additional, Lowe, Christopher F., additional, Pantophlet, Ralph, additional, Romney, Marc G., additional, Barrios, Rolando, additional, Guillemi, Silvia, additional, Brumme, Chanson J., additional, Montaner, Julio S.G., additional, Hull, Mark, additional, Harris, Marianne, additional, Niikura, Masahiro, additional, Brockman, Mark A., additional, and Brumme, Zabrina L., additional

Published
2022
Full Text
View/download PDF

13. People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses.

Author

Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Speckmaier S, Moran-Garcia N, Datwani S, Duncan MC, Agafitei O, Ennis S, Young L, Ali H, Ganase B, Omondi FH, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Pantophlet R, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, and Brumme ZL

Abstract

Background: Longer-term humoral responses to two-dose COVID-19 vaccines remain incompletely characterized in people living with HIV (PLWH), as do initial responses to a third dose., Methods: We measured antibodies against the SARS-CoV-2 spike protein receptor-binding domain, ACE2 displacement and viral neutralization against wild-type and Omicron strains up to six months following two-dose vaccination, and one month following the third dose, in 99 PLWH receiving suppressive antiretroviral therapy, and 152 controls., Results: Though humoral responses naturally decline following two-dose vaccination, we found no evidence of lower antibody concentrations nor faster rates of antibody decline in PLWH compared to controls after accounting for sociodemographic, health and vaccine-related factors. We also found no evidence of poorer viral neutralization in PLWH after two doses, nor evidence that a low nadir CD4+ T-cell count compromised responses. Post-third-dose humoral responses substantially exceeded post-second-dose levels, though anti-Omicron responses were consistently weaker than against wild-type.Nevertheless, post-third-dose responses in PLWH were comparable to or higher than controls. An mRNA-1273 third dose was the strongest consistent correlate of higher post-third-dose responses., Conclusion: PLWH receiving suppressive antiretroviral therapy mount strong antibody responses after two- and three-dose COVID-19 vaccination. Results underscore the immune benefits of third doses in light of Omicron.

Published
2022
Full Text
View/download PDF

14. Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third Dose.

Author

Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Datwani S, Omondi FH, Burns L, Young L, Leung V, Agafitei O, Ennis S, Dong W, Basra S, Lim LY, Ng K, Pantophlet R, Brumme CJ, Montaner JSG, Prystajecky N, Lowe CF, DeMarco ML, Holmes DT, Simons J, Niikura M, Romney MG, Brumme ZL, and Brockman MA

Abstract

Background: Third COVID-19 vaccine doses are broadly recommended, but immunogenicity data remain limited, particularly in older adults., Methods: We measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding domain, ACE2 displacement, and virus neutralization against ancestral and Omicron (BA.1) strains from pre-vaccine up to one month following the third dose, in 151 adults aged 24-98 years who received COVID-19 mRNA vaccines., Results: Following two vaccine doses, humoral immunity was weaker, less functional and less durable in older adults, where a higher number of chronic health conditions was a key correlate of weaker responses and poorer durability. Third doses boosted antibody binding and function to higher levels than second-doses, and induced responses in older adults that were comparable in magnitude to those in younger adults. Humoral responses against Omicron were universally weaker than against the ancestral strain after both second and third doses; nevertheless, after three doses, anti-Omicron responses in older adults reached equivalence to those in younger adults. After three vaccine doses, the number of chronic health conditions, but not age per se, was the strongest consistent correlate of weaker humoral responses., Conclusion: Results underscore the immune benefits of third COVID-19 vaccine doses, particularly in older adults.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results